Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services
The objectives are: (1) to determine if the C-THR intervention increases engagement in HIV prevention (i.e., HIV pre-exposure prophylaxis; PrEP or medications for opioid use disorder; MOUD) compared to non-SSP clinic referral and patient navigation, (2) to examine the long-term effectiveness and cost-effectiveness of the C-THR intervention, and (3) to assess the barriers and facilitators to implementation and sustainment of the C-THR intervention. The co-primary outcomes are PrEP or MOUD engagement across follow-up at 3, 6, 9 and 12 months. For PrEP, engagement is confirmed by tenofovir on dried blood spot or cabotegravir ...
Source: Addiction Science and Clinical Practice - March 26, 2024 Category: Addiction Authors: Tyler S Bartholomew Marina Plesons David P Serota Elizabeth Alonso Lisa R Metsch Daniel J Feaster Jessica Ucha Edward Suarez David W Forrest Teresa A Chueng Katrina Ciraldo Jimmie Brooks Justin D Smith Joshua A Barocas Hansel E Tookes Source Type: research
Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services
The objectives are: (1) to determine if the C-THR intervention increases engagement in HIV prevention (i.e., HIV pre-exposure prophylaxis; PrEP or medications for opioid use disorder; MOUD) compared to non-SSP clinic referral and patient navigation, (2) to examine the long-term effectiveness and cost-effectiveness of the C-THR intervention, and (3) to assess the barriers and facilitators to implementation and sustainment of the C-THR intervention. The co-primary outcomes are PrEP or MOUD engagement across follow-up at 3, 6, 9 and 12 months. For PrEP, engagement is confirmed by tenofovir on dried blood spot or cabotegravir ...
Source: Addiction Science and Clinical Practice - March 26, 2024 Category: Addiction Authors: Tyler S Bartholomew Marina Plesons David P Serota Elizabeth Alonso Lisa R Metsch Daniel J Feaster Jessica Ucha Edward Suarez David W Forrest Teresa A Chueng Katrina Ciraldo Jimmie Brooks Justin D Smith Joshua A Barocas Hansel E Tookes Source Type: research
Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services
The objectives are: (1) to determine if the C-THR intervention increases engagement in HIV prevention (i.e., HIV pre-exposure prophylaxis; PrEP or medications for opioid use disorder; MOUD) compared to non-SSP clinic referral and patient navigation, (2) to examine the long-term effectiveness and cost-effectiveness of the C-THR intervention, and (3) to assess the barriers and facilitators to implementation and sustainment of the C-THR intervention. The co-primary outcomes are PrEP or MOUD engagement across follow-up at 3, 6, 9 and 12 months. For PrEP, engagement is confirmed by tenofovir on dried blood spot or cabotegravir ...
Source: Addiction Science and Clinical Practice - March 26, 2024 Category: Addiction Authors: Tyler S Bartholomew Marina Plesons David P Serota Elizabeth Alonso Lisa R Metsch Daniel J Feaster Jessica Ucha Edward Suarez David W Forrest Teresa A Chueng Katrina Ciraldo Jimmie Brooks Justin D Smith Joshua A Barocas Hansel E Tookes Source Type: research
Viruses, Vol. 16, Pages 491: Profiling the Interaction between Human Serum Albumin and Clinically Relevant HIV Reverse Transcriptase Inhibitors
los Serpa
Tenofovir (TFV) is the active form of the prodrugs tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), both clinically prescribed as HIV reverse transcriptase inhibitors. The biophysical interactions between these compounds and human serum albumin (HSA), the primary carrier of exogenous compounds in the human bloodstream, have not yet been thoroughly characterized. Thus, the present study reports the interaction profile between HSA and TFV, TDF, and TAF via UV–Vis, steady-state, and time-resolved fluorescence techniques combined with isothermal titration calorimetry (ITC) and in...
Source: Viruses - March 22, 2024 Category: Virology Authors: Andreia Costa-Tuna Ot ávio A. Chaves Zaida L. Almeida Rita S. Cunha Jo ão Pina Carlos Serpa Tags: Article Source Type: research
Distinct Lipidomic Profiles between People Living with HIV Treated with E/C/F/TAF or B/F/TAF: An Open-Label Prospective Cohort Study
ConclusionE/C/F/TAF promotes the accumulation of lipid species closely associated with cardiovascular disease (CVD) risk among people living with HIV, whereas B/F/TAF has a decreased impact on CVD-related lipid profile and is associated with lower CVD risk.A graphical abstract is available with this article.Trial registrationClinicalTrials.gov; identifier, NCT06019273.Graphical Abstract (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - March 15, 2024 Category: Infectious Diseases Source Type: research
Contemporary Treatment Approaches for Human Immunodeficiency Virus Infection
Integrase inhibitors and tenofovir alafenamide have become a mainstay in modern antiretroviral therapy; more recently, they have been implicated as causing increased weight gain beyond what may be expected with the “return to health” phenomenon. Some patients, namely those assigned female at birth, of the black race, or with lower baseline CD4 counts, may be more likely to experience weight gain. This review outlines existing evidence linking the agents to excessive weight as well as ongoing efforts to com bat these effects. (Source: Nursing Clinics of North America)
Source: Nursing Clinics of North America - March 14, 2024 Category: Nursing Authors: Jenny Shroba, Jenna Januszka Source Type: research
Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in South Africa and Zimbabwe
Introduction
Oral pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention method; however, uptake and persistence have been low among southern African women. A dual prevention pill (DPP) that combines PrEP with oral contraception (OC) may increase PrEP use and better meet women’s sexual and reproductive health needs. We will gauge the DPP’s acceptability in two cross-over clinical trials.
Methods and analysis
PC952 (Zimbabwe) and PC953 (South Africa) will compare acceptability, adherence and preference for an over-encapsulated DPP versus PrEP and OCs taken separately. HIV-negative, non-pregnant ci...
Source: BMJ Open - March 12, 2024 Category: General Medicine Authors: Friedland, B. A., Mgodi, N. M., Palanee-Phillips, T., Mathur, S., Plagianos, M. G., Bruce, I. V., Lansiaux, M., Murombedzi, C., Musara, P., Dandadzi, A., Reddy, K., Ndlovu, N., Zulu, S. K., Shale, L. R., Zieman, B., Haddad, L. B. Tags: Open access HIV/AIDS Source Type: research
Thiazolidinediones Are Partially Effective Bitter Blockers
In this study, 2 TZDs were tested, rosiglitazone (ROSI) and a simpler form of TZD, using a high-potency sweetener as a positive control (neohesperidin dihydrochalcone, NHDC). We tested bitter-blocking effects using the bitter drugs tenofovir alafenamide fumarate (TAF), a treatment for HIV and hepatitis B infection, and praziquantel (PRAZ), a treatment for schistosomiasis, by conducting taste testing with 2 separate taste panels: a general panel (N = 97, 20-23 years, 82.5% female, all Eastern European) and a genetically informative panel (N = 158, including 68 twin pairs, 18-82 years, 76% female, 87% European ancestry). Par...
Source: Clinical Therapeutics - March 10, 2024 Category: Drugs & Pharmacology Authors: Ha Nguyen Cailu Lin Ivona Sasimovich Katherine Bell Amy Huang Emilia Leszkowicz Nancy E Rawson Danielle R Reed Source Type: research
Thiazolidinediones Are Partially Effective Bitter Blockers
In this study, 2 TZDs were tested, rosiglitazone (ROSI) and a simpler form of TZD, using a high-potency sweetener as a positive control (neohesperidin dihydrochalcone, NHDC). We tested bitter-blocking effects using the bitter drugs tenofovir alafenamide fumarate (TAF), a treatment for HIV and hepatitis B infection, and praziquantel (PRAZ), a treatment for schistosomiasis, by conducting taste testing with 2 separate taste panels: a general panel (N = 97, 20-23 years, 82.5% female, all Eastern European) and a genetically informative panel (N = 158, including 68 twin pairs, 18-82 years, 76% female, 87% European ancestry). Par...
Source: Clinical Therapeutics - March 10, 2024 Category: Drugs & Pharmacology Authors: Ha Nguyen Cailu Lin Ivona Sasimovich Katherine Bell Amy Huang Emilia Leszkowicz Nancy E Rawson Danielle R Reed Source Type: research
Thiazolidinediones Are Partially Effective Bitter Blockers
In this study, 2 TZDs were tested, rosiglitazone (ROSI) and a simpler form of TZD, using a high-potency sweetener as a positive control (neohesperidin dihydrochalcone, NHDC). We tested bitter-blocking effects using the bitter drugs tenofovir alafenamide fumarate (TAF), a treatment for HIV and hepatitis B infection, and praziquantel (PRAZ), a treatment for schistosomiasis, by conducting taste testing with 2 separate taste panels: a general panel (N = 97, 20-23 years, 82.5% female, all Eastern European) and a genetically informative panel (N = 158, including 68 twin pairs, 18-82 years, 76% female, 87% European ancestry). Par...
Source: Clinical Therapeutics - March 10, 2024 Category: Drugs & Pharmacology Authors: Ha Nguyen Cailu Lin Ivona Sasimovich Katherine Bell Amy Huang Emilia Leszkowicz Nancy E Rawson Danielle R Reed Source Type: research
Renal Adverse Effects of Tenofovir Containing Regimens in HIV-Infected Children and Adolescents in North India
CONCLUSION: TDF-containing ART regimen is associated with decreased eGFR, creatinine clearance and proteinuria.PMID:38449277 (Source: Indian Pediatrics)
Source: Indian Pediatrics - March 7, 2024 Category: Pediatrics Authors: Ravindra Kumar Mukesh Vir Singh Anubha Shrivastava Rajesh Kumar Yadav Shahid Akhtar Siddiqui Reena Sachan Manisha Maurya Nandita Mishra Santosh Kumar Shukla Madhu Sonkar Source Type: research
Renal Adverse Effects of Tenofovir Containing Regimens in HIV-Infected Children and Adolescents in North India
CONCLUSION: TDF-containing ART regimen is associated with decreased eGFR, creatinine clearance and proteinuria.PMID:38449277 (Source: Indian Pediatrics)
Source: Indian Pediatrics - March 7, 2024 Category: Pediatrics Authors: Ravindra Kumar Mukesh Vir Singh Anubha Shrivastava Rajesh Kumar Yadav Shahid Akhtar Siddiqui Reena Sachan Manisha Maurya Nandita Mishra Santosh Kumar Shukla Madhu Sonkar Source Type: research
Renal Adverse Effects of Tenofovir Containing Regimens in HIV-Infected Children and Adolescents in North India
CONCLUSION: TDF-containing ART regimen is associated with decreased eGFR, creatinine clearance and proteinuria.PMID:38449277 (Source: Indian Pediatrics)
Source: Indian Pediatrics - March 7, 2024 Category: Pediatrics Authors: Ravindra Kumar Mukesh Vir Singh Anubha Shrivastava Rajesh Kumar Yadav Shahid Akhtar Siddiqui Reena Sachan Manisha Maurya Nandita Mishra Santosh Kumar Shukla Madhu Sonkar Source Type: research
Renal Adverse Effects of Tenofovir Containing Regimens in HIV-Infected Children and Adolescents in North India
CONCLUSION: TDF-containing ART regimen is associated with decreased eGFR, creatinine clearance and proteinuria.PMID:38449277 (Source: Indian Pediatrics)
Source: Indian Pediatrics - March 7, 2024 Category: Pediatrics Authors: Ravindra Kumar Mukesh Vir Singh Anubha Shrivastava Rajesh Kumar Yadav Shahid Akhtar Siddiqui Reena Sachan Manisha Maurya Nandita Mishra Santosh Kumar Shukla Madhu Sonkar Source Type: research
